Good MorningThe S&P 500 tried to rebound on Wednesday but had trouble holding the gains. Hot labor data from ADP played into the idea the FOMC will not cut rates this summer and left the market wallowing near the previous day's low. If the market can not regain traction soon, a deeper correction is expected, and there is a risk of lower price action this week. The Non-Farm Payroll report is due on Friday and will likely confirm the ADP data. The two rarely align, but the trend is the same, and the trend in labor markets is solid. Because one of the two Fed mandates is satisfied and driving problems with the other, the FOMC will unlikely cut rates in the foreseeable future.
The S&P is signaling a peak; the question is if the downturn will be quick and shallow or long and deep, and the jury is still out. The FOMC is on track to cut rates, but it is unclear when. If there is no sign of recession, the market will likely recover from this downturn quickly and rally to new highs. If, however, signs of economic weakness emerge, a deep correction could follow.
Featured: 5 dividend stocks worth owning in any market condition (Ad) 
|
Basic Materials | |
Gold has reached new all-time highs, defying expectations amidst a robust U.S. economy and soaring stock markets. Its rally seems unstoppable, with gold trading at around $2,300 per ounce, marking an 11% increase year-to-date and a staggering 16% gain over the past 12 months.
Several factors con... Read the Full Story |
|
From Our Partners | | Renewed tensions involving Iran are putting global oil supplies back in focus - and history shows certain energy stocks respond before the broader market catches on.
A new report identifies three energy stocks emerging from today's supply disruptions. One is already benefiting from the current environment; the other two may not be on your radar yet. | | See which three energy stocks made the list and why they stand out |
|
Markets | |
Stock market bulls are back in control as major US indices have soared to new all-time highs to start 2024. Despite apprehension over inflation and high rates, bullish market trends have overtaken these concerns, in no small part thanks to exuberance over artificial intelligence innovation. But wh... Read the Full Story |
|
Medical | |
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The medical sector company addresses unmet needs in the segment. It received FDA approval for its lead candida... Read the Full Story |
|
From Our Partners | | Most AI portfolios hold the same handful of chip and software names - and completely ignore the physical layer. One perception-hardware company posted ~49% Q1 revenue growth with four partnership announcements in a single month.
A free report names seven companies building the automation, robotics, and semiconductor-test infrastructure that AI requires to move beyond the data center - including an automation giant that raised full-year guidance after quarterly sales rose ~12%. | | Click here to get your free copy of this report today |
|
Retail/Wholesale | |
Dave & Buster’s (NASDAQ: PLAY) investors can cheer the CQ1 results because it affirms a story played out over the years. The company leaned hard into growth, revenue quality, profitability, and capital returns yet failed to increase its share price. Now, the company is in rally mode, aid... Read the Full Story |
|
Finance | |
The momentum trade has been exhausted by the large-capitalization stocks in the market, especially those in the technology sector, as names like Nvidia Co. (NASDAQ: NVDA) keep making new all-time highs. For this reason, quants at PGIM believe that Wall Street may soon rotate into small-capitalizat... Read the Full Story |
|
From Our Partners | | Trader Graham Lindman has built a strategy around a repeating anomaly that appears in the first 60 minutes of every trading day - and it never requires holding positions overnight.
The setup has recently been refined to target up to 100% payouts by holding through the close, with 10 consecutive winning trades logged during one of the most volatile stretches since the Tariff Wars.
A new signal opportunity opens tomorrow. | | See how to join Graham Lindman's next trade before it opens |
|
Finance | |
Discount brokerages are here to stay, and Robinhood Markets Inc. (NASDAQ: HOOD) is one of the few that has earned the public’s heart, not to mention its capital. The company keeps adding new features to its platform, which was once considered for amateurs only. It now competes with The Charl... Read the Full Story |
|
Technology | |
Weibo (NASDAQ: WB) stock is deeply undervalued and ripe for a reversal. The stock is trading at only 5x its earnings, the lowest among China’s social media operators, and analysts see nothing but upside. Tepid results or not, China’s slow recovery or not, downward trending sentiment or... Read the Full Story |
|
Markets | |
As the overall market continues to break records and achieve new heights, speculation and optimism are rising. During such periods, stocks with unusually high short interest tend to outperform, as the overall market’s strength and bullish sentiment can overwhelm the fundamental reasons that ... Read the Full Story |
|
Finance | |
Mortgage REITs (mREITs) can be a valuable tool for investors seeking income and exposure to the real estate sector. However, their reliance on interest rates introduces a layer of complexity, particularly when the Federal Reserve is considering raising rates. Rising rates could send shockwaves thr... Read the Full Story |
|
Technology | |
The 17% drop from February’s peak, through the middle of last week might well have been a fair warning to investors of Braze, Inc (NASDAQ: BRZE), ahead of the company’s earnings last Wednesday. The customer engagement platform had been rallying all the way from the end of 2022 through ... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. | | View Today's Stock Pick |
|
